Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcus Biosciences (RCUS) EPS (Weighted Average and Diluted) (2019 - 2025)

Arcus Biosciences has reported EPS (Weighted Average and Diluted) over the past 7 years, most recently at -$0.9 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.9 for Q4 2025, up 12.62% from a year ago — trailing twelve months through Dec 2025 was -$3.31 (down 6.77% YoY), and the annual figure for FY2025 was -$3.29, down 4.78%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.9 at Arcus Biosciences, up from -$1.27 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for RCUS hit a ceiling of $3.99 in Q4 2021 and a floor of -$1.27 in Q3 2025.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$1.0 (2024), compared with a mean of -$0.67.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 558.62% in 2021, while the deepest fall reached 3800.0% in 2021.
  • Arcus Biosciences' EPS (Weighted Average and Diluted) stood at $3.99 in 2021, then crashed by 123.31% to -$0.93 in 2022, then dropped by 16.13% to -$1.08 in 2023, then increased by 4.63% to -$1.03 in 2024, then rose by 12.62% to -$0.9 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.9 (Q4 2025), -$1.27 (Q3 2025), and -$1.14 (Q1 2025) per Business Quant data.